HKSE - Delayed Quote HKD

Ascentage Pharma Group International (6855.HK)

Compare
33.950
-1.050
(-3.00%)
At close: January 28 at 12:08:04 PM GMT+8
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 6855.HK

Recent News: 6855.HK

View More

Ascentage Pharma Announces Closing of U.S. Initial Public Offering
GlobeNewswire 2 days ago

Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
GlobeNewswire 7 days ago
Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference

Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire last month
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months

Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
PR Newswire last month
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety

Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
PR Newswire last month
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
PR Newswire last month
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
PR Newswire last month
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report

Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
PR Newswire last month
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL
PR Newswire last month
New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List
PR Newswire 2 months ago
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
PR Newswire 2 months ago
View More

Related Tickers

1530.HK 3SBIO
6.010
-3.22%
 
9926.HK Akeso, Inc.
60.850
+1.76%
 
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
159.300
-0.62%
 
9688.HK Zai Lab Limited
20.900
+1.95%
 
1801.HK INNOVENT BIO
33.050
+0.15%
 
9969.HK InnoCare Pharma Limited
5.530
-2.81%
 
145020.KQ Hugel, Inc.
237,500.00
+2.81%
 
AKESF Akeso, Inc.
7.05
0.00%
 
6996.HK Antengene Corporation Limited
0.780
-1.27%
 
1877.HK JUNSHI BIO
11.000
-2.83%